KISSH, a dynamic player in the health care and medical devices sectors, was founded in 2018 and rapidly established itself as an innovation-driven entity in the diagnostic field. Specializing in in vitro pathological diagnosis and immunodiagnosis, they have developed a proprietary in vitro immunodiagnosis system targeting cancers along with versatile POCT product lines addressing infectious, genetic, and chronic diseases.
Leveraging their slogan, "Step Forward Every Second," KISSH emphasizes their progressive approach and commitment to shaping the future of in vitro diagnostic testing. A national high-tech enterprise, their strategic focus on emerging markets demonstrates potential for significant growth and impact.
The company secured a CNY10.00M Angel Round investment from Reading Capital in June 2019, underscoring investor confidence. As KISSH continues to expand its technological edge, it represents a promising opportunity for investors keen on health tech innovation.
Virax Biolabs
